Pruritis - Pipeline Insight, 2024

This Pruritis - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Pruritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pruritis Understanding

Pruritis: Overview

Pruritus, or itching, is a frequent complaint heard by dermatologists and primary care physicians. Although generally considered a benign symptom, pruritus can have adverse effects on a patient’s wellbeing and can be incapacitating when severe. The mechanisms of pruritus are not particularly well understood and are compounded by the subjective nature of the process itself. Pruritus occurs with a host of dermatological conditions, but can also be a marker of systemic disease. Dermatologists and primary care physicians must be aware of the varied causes of itching.

Pruritis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pruritis pipeline landscape is provided which includes the disease overview and Pruritis treatment guidelines. The assessment part of the report embraces, in depth Pruritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pruritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Pruritis R&D. The therapies under development are focused on novel approaches to treat/improve Pruritis.

This segment of the Pruritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pruritis Drugs
Linerixibat: GlaxoSmithKlineLinerixibat is an investigational product for the treatment of cholestatic pruritus in patients with PBC and it is not currently approved for use anywhere in the world. In 2019, FDA granted orphan drug designation for linerixibat in the treatment of PBC and associated cholestatic pruritus. Linerixibat is a minimally absorbed small molecule inhibitor of IBAT administered as an oral tablet. By blocking resorption of bile acids in the small intestine, linerixibat reduces pruritic bile acids in circulation.

Pruritis: Therapeutic Assessment

This segment of the report provides insights about the Pruritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pruritis

There are approx. 25+ key companies which are developing the therapies for Pruritis. The companies which have their Pruritis drug candidates in the most advanced stage, i.e. Phase III include GlaxoSmithKline.

Phases

This report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pruritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pruritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pruritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pruritis drugs.

Pruritis Report Insights

• Pruritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pruritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pruritis drugs?
• How many Pruritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pruritis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pruritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pruritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GlaxoSmithKline
• Chugai Pharmaceutical
• Regeneron/Sanofi
• DiverDrugs
• Atridia
• Asana BioSciences
• Vanda Pharmaceuticals
• Pfizer
• Trevi Therapeutics
• AbbVie
• Lumosa Therapeutics
• Luye Pharma Group

Key Products

• Linerixibat
• Nemolizumab
• Dupilumab
• Parentide
• SHR 0410
• ASN 008
• Tradipitant
• Abrocitinib
• Nalbuphine extended release
• Onabotulinum toxin A
• LT 5001
• BA 2101

This product will be delivered within 1-3 business days.